| Sangrose has been quick to recognize the importance
of developing knowledge-intensive business as drivers of future growth.
The focus on R&D as a key value driver has further strengthened the
overall business and growth horizon of the company. Sangrose aims to become
a partner of choice to select global pharma companies in terms of Active
Pharmaceutical Ingredient (API) & Novel Drug Delivery Systems (NDDS)
development |
| Our state of the art R&D is consistently working
to develop competitive products. Sangrose has all facilities ranging from
chemical process development to control and packing of API”s |
Continuous investment in R&D has enabled us to
develop innovative processes, products and technologies. By pioneering novel
ways of collating and managing information and knowledge, our ability to
pioneer novel production processes for »
Therapeutic molecules, is testimony to the path-breaking R&D
»
Capabilities and exceptional engineering skills. |
| The R&D in Sangrose is equipped with sophisticated
equipments and a well-trained research group working in a scientific environment
matching global standards. Several innovative processes have been developed
.The R&D is also backed by a full spectrum of library and information
management service. |